Adult Cancer Clinical Protocols
Open for Accrual August 1, 2008
Research Projects by Attending Physicians On Staff at Inova Fairfax Hospital Cancer Center
This list of open research trials is meant to be a general information resource only. This information is updated on a monthly basis. It should not replace or supercede information given by the patient's physician. These studies may close without warning.
In addition to the consent forms for these studies, additional general disease information can be found at www.cancer.gov. General information regarding clinical trials for patients can be found here. The U.S. government has a clinical trials web site that might also prove a helpful resource for patients. It allows people to look for trials in specific therapeutic areas: www.clinicaltrials.gov. The National Cancer Institute also has trial search engines and information on clinical trials.
For questions regarding the status of an individual study, please contact the person listed.
Site: Translational Research
Organization: Inova/George Mason University Translational Research
Institute
Title: Cancer Molecular Profiling Project
Purpose: To study the phosphoproteomic profile of brain, ovarian,
colorectal, liver, lung and hematogenous malignancies to classify
disease and develop treatments using microarray technology.
Principal Investigators: Kirsten Edmiston, MD, FACS, and Vikas
Chandhoke, PhD
Contact Person: Stacey Banks, 703-776-3565
Organization: International Genomics Consortium (IGC)
Title: The Expression Project for Oncology (expO)
Purpose: To perform gene expression analysis on breast, lung, colon,
ovary and prostate tumors and make all data publicly available with no
intellectual property restrictions
Principal Investigator: Nicholas Robert, MD
Contact Person: Stacey Banks, 703-776-3565
Site: Breast—Ductal Carcinoma in Situ
Organization: Inova/GMU Translational Research Institute
Title: Molecular Network Profiling of DCIS for
Patient Stratification and Individualized Therapy
Principal Investigator: Kirsten Edmiston, MD, FACS
Contact Person: Barbara Merritt, RN, BSN, 703-776-3551
Organization: Inova/GMU Translational Research
Institute/Dept. of Defense
Title: DCIS Stem Cells: A New Paradigm for
Invasion and Metastasis
Purpose: To identify and
propagate DCIS derived
neoplastic stem cells to assess growth and
metastasis.
Principal Investigator: Kirsten Edmiston, MD; Lance Liotta, MD
Contact Person: Barbara Merritt, RN, BSN, 703-776-3551
Site: Breast—Molecular Networks
Protocol: Inova/GMU Translational Research Institute
Title: Impact of Oral Hypoglycemic Usage on Breast
Cancer Gene Expression Patterns
Principal Investigator: Kirsten Edmiston, MD, FACS
Contact Person: Stacey Banks, 703-776-3565
Site: Breast—Adjuvant
Protocol: NCI
Title: JMA17R Ph III Letrozole vs Placebo in
Women w/5+ years
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN, 703-208-9258
Protocol: US Oncology 06-090
Title: A Phase III Trial of Adjuvant TC versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN, 703-208-9258
Protocol: ECOG
Title: TAILORx - Trial Assigning Individualized Options for Treatment
in Cancer Patients with Node -, ER+, PR+ Breast Cancer
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN, 703-208-9258
Protocol: ECOG E5103
Title: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed
by Paclitaxel and Bevacizumab or Placebo in Patients with Lymph
Node Positive and High Risk Lymph Node Negative Breast
Cancer
Principal Investigator: Mary Wilkinson, MD
Contact Person: Carol Hatch, RN, 703-720-5210
Protocol: SWOG S0307
Title: Phase III Trial of Bisphosphonates as Adjuvant
Therapy for Primary Breast Cancer
Principal Investigator: Mary Wilkinson, MD
Contact Person: Carol Hatch, RN, 703-720-5210
Site: Breast—Metastatic
Protocol: US Oncology 07-040
Title: A Phase II, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin,
with or without BSI-201, in
patients with ER, PR, and HER2-negative Metastatic Breast Cancer
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN, 703-208-9258
Protocol: US Oncology 07-036
Title: Taxol+Sutent v Taxol+Avastin
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN, 703-208-9258
Protocol: Georgetown 2004-251
Title: Phase I/II Trial of Sorafenib in combintion with
Anastrozole in Patients with Metastatic Breast
Cancer
Principal Investigator: Mary Wilkinson, MD
Contact Person: Carol Hatch, RN, 703-720-5210
Protocol: Georgetown 2005-200
Title: Circulating Tumor Cells: Assessment of Treatment
Efficacy in Metastatic Breast Cancer
Principal Investigator: Mary Wilkinson, MD
Contact Person: Carol Hatch, RN, 703-720-5210
Site: Bladder/Gastric/Esophageal/Ovarian/ Uterine
Protocol: US Oncology 06-063
Title: Phase II Docetaxel+Oxali+Cetux
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN, 703-208-9258
Site: Colorectal Cancer
No studies at this time.
Site: Lung—Adjuvant
Protocol: START
Title: Study of vaccine STIMUVAX in Pts with
Unresectable Stage III
Disease
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN,
703-208-9258
Protocol: HGS
Title: Ph II Mapatumumab + Carboplatin + Paclitaxel (Fairfax
office only)
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN, 703-208-9258
Site: Multiple Myeloma
Protocol: US Oncology 06-108
Title: Randomized
Phase IIIb Study of Three Treatment Regimens in Subjects
with Previously Untreated Multiple Myeloma Who Are Not
Considered Candidates for High-Dose Chemotherapy and
Autologous Stem Cell Transplantation: VELCADE®
(Bortezomib), Thalidomide, and
Dexamethasone (VTD) versus
VELCADE® and Dexamethasone (VD)
versus VELCADE®, Melphalan and
Prednisone (VMP)
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN,
703-208-9258
Site: Ovarian/Fallopian Tube or Peritoneal Cancer
Protocol: Gynecological Oncology Group (GOG 0209)
Title: Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel
and G-CSF Versus Carboplatin/Paclitaxel in Patients
with Stage III and IV or Recurrent
Endometrial Cancer
Principal Investigator: John C. Elkas, MD
Contact Person: Sheila Whitt, RN703-698-7100
Protocol: Gynecological Oncology Group (GOG 212)
Title: A randomized phase III trial of maintenance
chemotherapy comparing 12
monthly cycles of single agent paclitaxel or xyotax versus no treatment until
documented relapse in women with advanced ovarian or
primary ovarian peritoneal cancer
who achieve a complete clinical response to primary platinum/taxane
chemotherapy
Principal Investigator: John C. Elkas, MD
Contact Person: Sheila Whitt, RN, 703-698-7100
Protocol: Gynecological Oncology Group (GOG 218)
Title: A Phase III
Trial of carboplatin and paclitaxel
plus placebo versus carboplatin and paclitaxel plus concurrent bevacizumab
followed by placebo, versus carboplatin and paclitaxel, plus
concurrent and extended bevacizumab, in
women with newly diagnosed, previously untreated, stage III
(suboptimal) and all
stage IV, epithelial ovarian or primary peritoneal cancer
Principal Investigator: John C. Elkas, MD
Contact Person: Sheila Whitt, RN, 703-698-7100
Protocol: Gynecological Oncology Group (GOG 0219)
Title:
Phase III, Randomized Trial of Weekly Cisplatin and Radiation versus
Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB
and IVA Cervical Carcinoma Limited to the Pelvis
Principal Investigator: John C. Elkas, MD
Contact Person: Sheila Whitt, RN, 703-698-7100
Protocol: Novartis
Title: A randomized, parallel group, open-label, active controlled, multi-center
Phase III trial of Patupilone (EPO906) versus Pegylated
liposomal doxorubicin
(Doxil®/Caelyx®) in taxane/platinum
refractory/resistant patients with recurrent
epithelial ovarian, primary fallopian or primary
peritoneal cancer
Principal Investigator: Annette Bicher, MD
Contact Person: Sheila Whitt, RN, 703-698-7100
Protocol: Genetech
Title: A Phase II multi-center, Randomized, blinded, placebo-controlled trial of Carboplatin and Gemcitabine plus Bevacizumab
in patients with platinum sensitive recurrent ovary, primary
peritoneal, or fallopian tube carcinoma
Primary Investigator: Annette Bicher, MD
Contact Person: Sheila Whitt, RN, 703-698-7100
Protocol: Marshall Edwards OVATURE
Title: Phase III Efficacy Study comparing Phenoxodiol
(oral dose form) in combination with Carboplatin with placebo in
patients with platinum-resistant or platinum-refractory late stage epithelial ovarian, fallopian or
primary peritoneal cancer following at least second line
platinum therapy
Primary Investigator: Annette Bicher, MD
Contact Person: Sheila Whitt, RN, 703-698-7100
Site: Prostate
Protocol: US Oncology 07-068
Title: A
Randomized, Double Blind, Placebo Controlled,
Multicenter, Phase II Study
Comparing AT-101 in Combination with Docetaxel
and Prednisone versus Docetaxel and Prednisone in Men with
Chemotherapy Naïve
Metastatic Hormone Refractory Prostate Cancer (HRPC)
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN, 703-208-9258
Site: Sarcoma
Protocol: ARAID
Title: Efficacy of AP23573 for Patients Completing 1, 2, or 3 Lines
of Prior Therapy Achieving SD, PR, or CR (Fairfax office only)
Principal Investigator: Nicholas Robert, MD
Contact Person: Ellen Ritter, RN, 703-208-9258
Site: Advanced Cancers
No studies at this time.
